She Started an Oxybate, but Didn’t Stay on It: Managing Expectations and Adherence - CME - Guideline Central

CME

Title
She Started an Oxybate, but Didn’t Stay on It: Managing Expectations and Adherence
Link
Description
Overcoming the operational hurdles of Risk Evaluation and Mitigation Strategy (REMS) and prior authorization is only the first step in successful narcolepsy management. Clinicians frequently encounter high rates of treatment discontinuation once oxybate therapy begins. In this focused discussion, sleep medicine experts Michael Thorpy, MD, and Kiran Maski, MD, MPH, explore the root causes of oxybate discontinuation, specifically the logistical burden of twice-nightly dosing, nocturnal safety risks, and the impact of non-linear pharmacokinetics. Participants will learn valuable strategies, including "slow and low" titration and proactive counseling, designed to align clinical expectations with the realities of narcolepsy therapy. By improving the clinical team’s competence in managing dosing-related barriers—including the transition to once-nightly formulations for patients struggling with nocturnal awakening—this activity transforms the management of oxybate therapy from a source of patient frustration into an opportunity for long-term adherence and improved wakefulness.
Target Audience
The activity is designed for US-based clinicians (eg, physicians, nurse practitioners [NPs], and physician associates [PAs]) who diagnose or treat central disorders of hypersomnolence (CDH), including clinicians who specialize in sleep medicine, neurology, psychiatry, or pulmonology.
Learning Objectives
  • Apply strategies to overcome barriers to the use of oxybates for narcolepsy, including REMS and insurance requirements, controlled substance restrictions, abuse potential, safety risks, dosing inconvenience, and drug-drug interactions.
Estimated Duration
15 minutes
Delivery Mode
Online
Format
Online Learning
Specialties
Psychiatry, Pulmonology, Neurology, Sleep Medicine
Keywords
sleep medicine, Oxybate
Disclosures and Disclaimers
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education or Avadel CNS Pharmaceuticals, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Accredited Providers
  • Haymarket Medical Education
Commercial Support
  • Avadel CNS Pharmaceuticals, LLC
Activity Expiration Date
April 10, 2027
Credit Information
Credit TypeUnits / Unit TypeBoard
AMA PRA Category 1 Credit0.25 CreditsACCME- Accreditation Council for Continuing Medical Education
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.